Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. (Q38677904)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

title

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

5

Zhiqiang Wu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Kaichao Feng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Yang Liu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Yelei Guo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Jingdan Qiu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Hanren Dai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Qingming Yang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Yao Wang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Weidong Han

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

publication date

14 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

838-847

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

25 March 2020

copyright license

start time

14 July 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

The biliary tree--a reservoir of multipotent stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Biliary tract cancers: understudied and poorly understood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Driving gene-engineered T cell immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Prospects for gene-engineered T cell immunotherapy for solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Molecular genetics and targeted therapeutics in biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

HER2 expression status in diverse cancers: review of results from 37,992 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13238-017-0440-4

Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28710747

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28710747

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Therapeutic implication of HER2 in advanced biliary tract cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28710747

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13238-017-0440-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

25 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28710747%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

PubMed publication ID

28710747

1 reference